IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available for virtual one-on-one meetings throughout the day. Interested investors should visit https://ibn.fm/AiqIk to register for the webinar and view the live presentation.
To view the full press release, visit https://ibn.fm/M3rGV
About IGC Pharma Inc.
IGC Pharma is a clinical stage biotechnology company developing advanced cannabinoid-based formulations for treating diseases and conditions including Alzheimer’s, dysmenorrhea, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease: IGC-AD1 and TGR-63. IGC-AD1, currently advancing through a phase 2 safety and efficacy clinical trial as a treatment for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). IGC Pharma is committed to developing impactful drug formulations that meaningfully improve the life of patients suffering from a broad range of diseases and conditions. For more information visit www.IGCPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
